Latest news
FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients - Endpoints NewsEndpoints News · Mon, 03 Aug 2026 15:26:00 GMTNovartis Pluvicto FDA approval doubles mHSPC patient pool - scanx.tradescanx.trade · Mon, 03 Aug 2026 15:07:31 GMTNovartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer - Fierce PharmaFierce Pharma · Mon, 03 Aug 2026 12:33:04 GMTNovartis (SWX:NOVN) Wins FDA Approval For Pluvicto In Earlier Prostate Cancer - Yahoo FinanceYahoo Finance · Sun, 02 Aug 2026 10:06:47 GMTNovartis wins FDA approval for Pluvicto in earlier-line PSMA+ prostate cancer - DealroomDealroom · Sat, 01 Aug 2026 09:20:02 GMTFDA Expands Approval of Pluvicto in Combination with ARPI for PSMA-Positive mAPMN/S Prostate Cancer - diagnosticimaging.comdiagnosticimaging.com · Sat, 01 Aug 2026 07:00:00 GMTPluvicto in Metastatic Hormone-Sensitive Prostate Cancer - Prostate Cancer Foundation (PCF)Prostate Cancer Foundation (PCF) · Fri, 31 Jul 2026 07:00:00 GMT